251 related articles for article (PubMed ID: 29991926)
1. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.
Jung RG; Motazedian P; Ramirez FD; Simard T; Di Santo P; Visintini S; Faraz MA; Labinaz A; Jung Y; Hibbert B
Thromb J; 2018; 16():12. PubMed ID: 29991926
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention.
Jung RG; Simard T; Di Santo P; Dhaliwal S; Sypkes C; Duchez AC; Moreland R; Taylor K; Parlow S; Visintini S; Labinaz A; Marbach J; Sarathy K; Bernick J; Joseph J; Boland P; Abdel-Razek O; Harnett DT; Ramirez FD; Hibbert B
Thromb Res; 2020 Jul; 191():125-133. PubMed ID: 32447094
[TBL] [Abstract][Full Text] [Related]
3. Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease.
Zhang AY; Ji XW; Zhang AJ; Guan LX; Huang J; Wang JX
Cardiol Res; 2010 Dec; 1(1):8-14. PubMed ID: 28352370
[TBL] [Abstract][Full Text] [Related]
4. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
Zunker P; Schick A; Padró T; Kienast J; Phillips A; Ringelstein EB
Neurol Res; 1999 Dec; 21(8):727-32. PubMed ID: 10596380
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
6. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
7. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
Strauss BH; Lau HK; Bowman KA; Sparkes J; Chisholm RJ; Garvey MB; Fenkell LL; Natarajan MK; Singh I; Teitel JM
Circulation; 1999 Oct; 100(15):1616-22. PubMed ID: 10517732
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen Activator Inhibitor-1 Levels in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Alsharoh H; Ismaiel A; Leucuta DC; Popa SL; Dumitrascu DL
J Gastrointestin Liver Dis; 2022 Jun; 31(2):206-214. PubMed ID: 35574617
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
Tofler GH; Massaro J; O'Donnell CJ; Wilson PWF; Vasan RS; Sutherland PA; Meigs JB; Levy D; D'Agostino RB
Thromb Res; 2016 Apr; 140():30-35. PubMed ID: 26896607
[TBL] [Abstract][Full Text] [Related]
10. Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials.
Sahebkar A; Catena C; Ray KK; Vallejo-Vaz AJ; Reiner Ž; Sechi LA; Colussi G
Thromb Haemost; 2016 Jul; 116(1):162-71. PubMed ID: 27009446
[TBL] [Abstract][Full Text] [Related]
11. Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Golukhova EZ; Grigorian MV; Ryabinina MN; Bulaeva NI; Fortmann S; Serebruany VL
Cardiology; 2015; 132(3):176-81. PubMed ID: 26277984
[TBL] [Abstract][Full Text] [Related]
12. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting.
Marcucci R; Brogi D; Sofi F; Giglioli C; Valente S; Liotta AA; Lenti M; Gori AM; Prisco D; Abbate R; Gensini GF
Heart; 2006 Mar; 92(3):377-81. PubMed ID: 15994914
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
Ding J; Nicklas BJ; Fallin MD; de Rekeneire N; Kritchevsky SB; Pahor M; Rodondi N; Li R; Zmuda JM; Harris TB
Am Heart J; 2006 Dec; 152(6):1109-15. PubMed ID: 17161063
[TBL] [Abstract][Full Text] [Related]
14. Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea.
Bagai K; Muldowney JA; Song Y; Wang L; Bagai J; Artibee KJ; Vaughan DE; Malow BA
Sleep; 2014 Feb; 37(2):359-67. PubMed ID: 24497664
[TBL] [Abstract][Full Text] [Related]
15. Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials.
Sahebkar A; Simental-Mendía LE; Watts GF; Golledge J
Atherosclerosis; 2015 May; 240(1):284-96. PubMed ID: 25828270
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction.
Gray RP; Patterson DL; Yudkin JS
Arterioscler Thromb; 1993 Mar; 13(3):415-20. PubMed ID: 8443145
[TBL] [Abstract][Full Text] [Related]
17. Association of Elevated Plasma Homocysteine Level with Restenosis and Clinical Outcomes After Percutaneous Coronary Interventions: a Systemic Review and Meta-analysis.
Zhang Z; Xiao S; Yang C; Ye R; Hu X; Chen X
Cardiovasc Drugs Ther; 2019 Jun; 33(3):353-361. PubMed ID: 30778807
[TBL] [Abstract][Full Text] [Related]
18. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
McBane RD; Hardison RM; Sobel BE;
Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
[TBL] [Abstract][Full Text] [Related]
19. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects.
Liu Y; Cheng J; Guo X; Mo J; Gao B; Zhou H; Wu Y; Li Z
Gene; 2018 Oct; 673():167-173. PubMed ID: 29908999
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
